Amendment No. 1 to Research Agreement Between University of Miami and Epien Medical (January 25, 2022)

Exhibit 10.16

RESEARCH AGREEMENT

Amendment No. 1

(Non-Clinical)

This Amendment (“Amendment”) entered into this 25th day of January, 2022 (“Amendment Effective Date”), by and between the University of Miami, (“University”) and Epien Medical (“Company”) amends the agreement between the parties dated August 20, 2021 (“Agreement”) which is incorporated by referenced herein and made part of this Amendment.

Whereas, University and Company entered into the Agreement for the a study entitled: Determination of the Debridement Effects of Revity on Deep Dermal Wounds in a Porcine Model (“Study”).

Whereas, University and Company intend to amend the Agreement as follows:

1. The amount of funding for the conduct of the Study is being increased by $15,541.00. The total amount of funding is hereby amended to a total of $38,902.00.

2. Except as expressly provided in this Amendment, all other terms, conditions and provisions of the Agreement shall apply and remain in full force and effect. All terms used herein shall have the same meaning as ascribed to them in the Agreement. To the extent any term or provision of this Amendment conflicts with any term or provision of the Agreement, the terms and provisions of this Amendment shall prevail.

[Remainder of page left intentionally blank]

IN WITNESS THEREOF, the parties have executed this Amendment by their duly authorized officers or representatives:

UNIVERSITY OF MIAMI:
/s/ D. Stewart MacIntyre III, JD
Authorized University Representative
D. Stewart MacIntyre III, JD
Director, Office of Research Administration
Name and Title
Feb 22, 2022
Date